| Literature DB >> 30863395 |
Maximilian Hörner1,2,3, Julian Eble1,2, O Sascha Yousefi1,2,3, Jennifer Schwarz1,3, Bettina Warscheid1,2,3, Wilfried Weber1,2,3, Wolfgang W A Schamel1,2,3,4.
Abstract
Multiprotein complexes control the behavior of cells, such as of lymphocytes of the immune system. Methods to affinity purify protein complexes and to determine their interactome by mass spectrometry are thus widely used. One drawback of these methods is the presence of false positives. In fact, the elution of the protein of interest (POI) is achieved by changing the biochemical properties of the buffer, so that unspecifically bound proteins (the false positives) may also elute. Here, we developed an optogenetics-derived and light-controlled affinity purification method based on the light-regulated reversible protein interaction between phytochrome B (PhyB) and its phytochrome interacting factor 6 (PIF6). We engineered a truncated variant of PIF6 comprising only 22 amino acids that can be genetically fused to the POI as an affinity tag. Thereby the POI can be purified with PhyB-functionalized resin material using 660 nm light for binding and washing, and 740 nm light for elution. Far-red light-induced elution is effective but very mild as the same buffer is used for the wash and elution. As proof-of-concept, we expressed PIF-tagged variants of the tyrosine kinase ZAP70 in ZAP70-deficient Jurkat T cells, purified ZAP70 and associating proteins using our light-controlled system, and identified the interaction partners by quantitative mass spectrometry. Using unstimulated T cells, we were able to detect the known interaction partners, and could filter out all other proteins.Entities:
Keywords: ZAP70; affinity purification; mass spectrometry; optogenetics; phytochrome; protein-protein interaction
Mesh:
Substances:
Year: 2019 PMID: 30863395 PMCID: PMC6399385 DOI: 10.3389/fimmu.2019.00226
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Light-controlled affinity purification of proteins. The protein of interest (POI) is expressed in the desired cells as a fusion protein with a truncated variant of phytochrome interacting factor 6 (PIF) serving as the affinity tag. Biotinylated phytochrome B (PhyB*) is immobilized on NeutrAvidin (N)-functionalized agarose beads. Following cell lysis, the POI is bound via its PIF tag to PhyB* under 660 nm light. After washing to remove unspecifically bound proteins under continued 660 nm illumination, PIF-POI is eluted in washing buffer from PhyB* beads by switching illumination to 740 nm light. Interaction partners (1–3) of the POI are co-purified.
Figure 2Evaluation of different truncated variants of PIF6 for the application as an affinity tag. (A) Design of the expression construct for testing of different affinity tags. GFP was fused to the depicted PIF6 variants or to the affinity tags TEVCS-ProteinA or SBP. The fusion proteins were expressed together with the untagged red fluorescent protein mCherry by a constitutive CMV promoter in human embryonic kidney cells (HEK-293T). IRES, internal ribosomal entry site; pA, poly(A) tail. (B) Monitoring of the light-controlled affinity purification process. Fluorescence of GFP and of the background control mCherry was measured using a plate reader and is shown as percentage normalized to the fluorescence of the initial cell lysate. For each replicate, 4 × 106 cells were lysed in 500 μl lysis buffer and proteins were purified with 50 μl of PhyB* beads. The proteins were eluted at 740 nm light for 30 min. FT, flow-through; W1-W3, wash 1-3. Data are means ± s.d. (n = 2). (C) Comparison of the purity of light-controlled affinity purification [PIF6(15-36) and PIF6(1-100)] with established purification methods (TEVCS-ProteinA and SBP). For each purification, 125 × 106 cells were lysed with 500 μl of lysis buffer and purified with 100 μl of beads and four washing steps. Coomassie-stained SDS-PAGE gel of the eluates is shown.
Figure 3Characterization of the light-controlled affinity purification system. Lysates of HEK-293T cells containing mCherry and GFP-PIF6(1-100) or GFP-PIF6(15-36) as described in Figure 2A were used. (A) Binding efficiency and capacity of PhyB* beads. Different amounts of PhyB* beads were each incubated with 250 μl of cell lysate containing 1.5 nmol GFP-PIF6(1-100) or GFP-PIF6(15-36) for 2 h at 660 nm illumination. Afterwards, the ratio of bound protein was determined by measuring fluorescence of unbound GFP and mCherry. (B) Binding kinetics. Equal amounts of PhyB* beads (20 μl) were incubated with 125 μl of cell lysate containing 0.75 nmol of GFP-PIF6(1-100) or GFP-PIF6(15-36) for the indicated time periods under 660 nm light. Subsequently, the ratio of bound protein was determined by measuring fluorescence of unbound GFP and mCherry. (C) Elution kinetics. Equal amounts of PhyB* beads (40 μl) were incubated with 500 μl of cell lysate containing 3.0 nmol of GFP-PIF6(1-100) or GFP-PIF6(15-36) for 1 h at 660 nm illumination. After washing, the beads were incubated in 500 μl of wash buffer for the indicated times at 740 nm light for elution. The percentage of eluted protein was calculated by determining GFP fluorescence in the supernatant in comparison to the GFP amount on the beads before elution. All data are means ± s.d. (n = 3).
Figure 4Generation and characterization of P116-based cell lines stably expressing ZAP70-PIF6(1-100) or ZAP70-PIF6(15-36). (A) Lentiviral vectors encoding the depicted constructs for expression of ZAP70-PIF6(1-100) or ZAP70-PIF6(15-36) and the fluorescent protein ZsGreen1 under control of the constitutive CMV promoter (PCMV). Transduced P116 cells were sorted based on ZsGreen1 fluorescence. (B) After culturing the two sorted cell lines generated in (A), ZsGreen1 fluorescence of the cell lines in comparison to parental P116 cells was analyzed by flow cytometry. (C) Expression of ZAP70 in different cell lines. The cell lines indicated were analyzed for ZAP70 and GAPDH expression by SDS-PAGE and Western blotting. (D) Restoring anti-CD3 induced Ca2+-flux in P116 cells stably expressing ZAP70-PIF6(1-100) or ZAP70-PIF6(15-36). The Indo-1 fluorescence of Indo-1-stained cells was measured by flow cytometry, as a readout for the intracellular Ca2+ concentration. After 240 s of the recording the cells were stimulated with 1 μg ml−1 of an anti-CD3 antibody (indicated by the arrow).
Figure 5Analysis of light-controlled ZAP70-PIF purification by mass spectrometry. Jurkat cells and P116-derived cell lines stably expressing ZAP70-PIF6(1-100) or ZAP70-PIF6(15-36) were lysed and PIF-tagged proteins were light-controlled purified using PhyB* beads (n = 3 biological replicates). All eluates and the flow-throughs of the last washing were analyzed by mass spectrometry. (A) Analysis of the cell lysates, the flow-throughs of the last washing step and the eluates by SDS-PAGE and Western blot against ZAP70 and GAPDH. (B) Comparison of the 20 best hits (p < 0.05, sorted on protein enrichment) enriched in the eluates of each ZAP70-PIF6 cell line vs. the eluates from the Jurkat cell line. Known interaction partners of ZAP70 are written in bold. (C) Enrichment of proteins identified in the ZAP70-PIF6(1-100) eluate vs. the Jurkat eluate (x-axis) plotted against the enrichment of proteins in the ZAP70-PIF6(15-36) eluate vs. the Jurkat eluate (y-axis). The enrichment for each protein is shown as the mean log10 ratio of the label-free quantification (LFQ) intensities (3 biological replicates) of the compared samples. Known interaction partners of ZAP70 identified in (B) are highlighted in black and are labeled. All significant hits (p < 0.05) in the upper right quadrant are highlighted in red. The POI ZAP70 is highlighted in yellow. Dashed lines represent a ratio cut-off corresponding to a 3-fold enrichment compared to the Jurkat eluate. (D) Comparison of the 20 best hits (p < 0.05, sorted on protein enrichment) enriched in the eluates of each ZAP70-PIF6 cell line vs. the flow-throughs of the last washing step. Known interaction partners of ZAP70 are written in bold. CHCHD2/P9, CHCHD2, CHCHD2P9; CD247-i3, CD247 isoform 3; TRBC1/2, TRBC1, TRBC2.
Figure 6Usage of two controls to confine the data to the most relevant interaction partners of the POI ZAP70. (A,B) Comparison of the 20 best hits (p < 0.05, sorted on protein enrichment) enriched in the eluates of the ZAP70-PIF6(1-100) (A)/ZAP70-PIF6(15-36) (B) cell line vs. the eluates from the Jurkat cell line or the flow-throughs of the last washing step. Known interaction partners of ZAP70 are written in bold. (C,D) Enrichment of proteins identified in the ZAP70-PIF6(1-100) (C)/ZAP70-PIF6(15-36) (D) eluates vs. the Jurkat eluates (x-axis) plotted against the enrichment of proteins in the ZAP70-PIF6(1-100) (C)/ZAP70-PIF6(15-36) (D) eluates vs. the corresponding flow-throughs of the last washing step (y-axis). The enrichment for each protein is shown as the mean log10 ratio of the label-free quantification (LFQ) intensities (3 biological replicates) of the compared samples. Known double-positive interaction partners of ZAP70 identified within the TOP 20 hits in (A)/(B) are highlighted in black and the names are indicated; the remaining hits of the TOP 20 are highlighted as bold black circles filled with the color corresponding to the group color used in the VENN diagram in (A)/(B). The POI ZAP70 is highlighted in yellow. Dashed lines represent a ratio cut-off corresponding to a 3-fold or 2-fold enrichment. CHCHD2/P9, CHCHD2, CHCHD2P9; CD247-i3, CD247 isoform 3; TRBC1/2, TRBC1, TRBC2.